14 reports of this reaction
3.2% of all MINERAL OIL, PETROLATUM, PHENYLEPHRINE HCL reports
#3 most reported adverse reaction
RECTAL HAEMORRHAGE is the #3 most commonly reported adverse reaction for MINERAL OIL, PETROLATUM, PHENYLEPHRINE HCL, manufactured by Haleon US Holdings LLC. There are 14 FDA adverse event reports linking MINERAL OIL, PETROLATUM, PHENYLEPHRINE HCL to RECTAL HAEMORRHAGE. This represents approximately 3.2% of all 436 adverse event reports for this drug.
Patients taking MINERAL OIL, PETROLATUM, PHENYLEPHRINE HCL who experience rectal haemorrhage should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RECTAL HAEMORRHAGE is moderately reported among MINERAL OIL, PETROLATUM, PHENYLEPHRINE HCL users, representing a notable but not dominant share of adverse events.
In addition to rectal haemorrhage, the following adverse reactions have been reported for MINERAL OIL, PETROLATUM, PHENYLEPHRINE HCL:
The following drugs have also been linked to rectal haemorrhage in FDA adverse event reports:
RECTAL HAEMORRHAGE has been reported as an adverse event in 14 FDA reports for MINERAL OIL, PETROLATUM, PHENYLEPHRINE HCL. This does not prove causation, but indicates an association observed in post-market surveillance data.
RECTAL HAEMORRHAGE accounts for approximately 3.2% of all adverse event reports for MINERAL OIL, PETROLATUM, PHENYLEPHRINE HCL, making it one of the most commonly reported side effect.
If you experience rectal haemorrhage while taking MINERAL OIL, PETROLATUM, PHENYLEPHRINE HCL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.